Published in Infect Immun on November 01, 2005
Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe (2009) 2.17
Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines (2008) 1.71
Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis. Immunol Rev (2008) 1.48
Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect Immun (2006) 1.47
Immune defense against pneumonic plague. Immunol Rev (2008) 1.44
The yersiniabactin transport system is critical for the pathogenesis of bubonic and pneumonic plague. Infect Immun (2010) 1.32
Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication. J Immunol (2009) 1.28
CD8(+) T cells restrict Yersinia pseudotuberculosis infection: bypass of anti-phagocytosis by targeting antigen-presenting cells. PLoS Pathog (2009) 1.24
Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect Immun (2006) 1.24
Proinflammatory microenvironments within the intestine regulate the differentiation of tissue-resident CD8⁺ T cells responding to infection. Nat Immunol (2015) 1.19
IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection. J Immunol (2010) 1.10
Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients. Clin Vaccine Immunol (2011) 1.10
Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Eur J Immunol (2008) 1.10
The smpB-ssrA mutant of Yersinia pestis functions as a live attenuated vaccine to protect mice against pulmonary plague infection. Infect Immun (2010) 1.07
Antibodies and cytokines independently protect against pneumonic plague. Vaccine (2008) 1.06
TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine (2010) 1.04
The role of relA and spoT in Yersinia pestis KIM5 pathogenicity. PLoS One (2009) 1.01
Interaction between Yersinia pestis and the host immune system. Infect Immun (2008) 0.98
Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague. Infect Immun (2010) 0.98
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine (2008) 0.97
TNFα and IFNγ but not perforin are critical for CD8 T cell-mediated protection against pulmonary Yersinia pestis infection. PLoS Pathog (2014) 0.97
D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague. Infect Immun (2009) 0.96
A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis. Infect Immun (2011) 0.96
Protecting against plague: towards a next-generation vaccine. Clin Exp Immunol (2013) 0.95
A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infect Immun (2008) 0.92
High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay. Infect Immun (2009) 0.92
YopJ-promoted cytotoxicity and systemic colonization are associated with high levels of murine interleukin-18, gamma interferon, and neutrophils in a live vaccine model of Yersinia pseudotuberculosis infection. Infect Immun (2010) 0.92
Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine (2011) 0.89
Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor. Vaccine (2012) 0.88
Yersinia pestis AcrAB-TolC in antibiotic resistance and virulence. Antimicrob Agents Chemother (2011) 0.86
Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice. Vaccine (2010) 0.85
The role of macrophage migration inhibitory factor in the cascade of events leading to reperfusion-induced inflammatory injury and lethality. Am J Pathol (2007) 0.85
Protection against pneumonic plague following oral immunization with a non-replicating vaccine. Vaccine (2010) 0.83
Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis. J Immunol (2013) 0.83
Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection. Infect Immun (2013) 0.82
Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines. PLoS Pathog (2013) 0.81
Development of virus-like particles for diagnostic and prophylactic biomedical applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.80
An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague. Vaccine (2008) 0.80
A parenteral DNA vaccine protects against pneumonic plague. Vaccine (2010) 0.79
Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague. Clin Vaccine Immunol (2011) 0.79
Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague. Int J Nanomedicine (2014) 0.79
LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague. Infect Immun (2014) 0.79
Histopathological observation of immunized rhesus macaques with plague vaccines after subcutaneous infection of Yersinia pestis. PLoS One (2011) 0.79
Highly Effective Soluble and Bacteriophage T4 Nanoparticle Plague Vaccines Against Yersinia pestis. Methods Mol Biol (2016) 0.79
Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaques. Hum Vaccin Immunother (2013) 0.78
Recombinant Bivalent Fusion Protein rVE Induces CD4+ and CD8+ T-Cell Mediated Memory Immune Response for Protection Against Yersinia enterocolitica Infection. Front Microbiol (2015) 0.77
The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague. Adv Prev Med (2011) 0.77
The role of transition metal transporters for iron, zinc, manganese, and copper in the pathogenesis of Yersinia pestis. Metallomics (2015) 0.77
HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model. PLoS Negl Trop Dis (2014) 0.77
Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion. Vaccine (2011) 0.77
Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague. Vaccine (2015) 0.76
In vivo transcriptional profiling of Yersinia pestis reveals a novel bacterial mediator of pulmonary inflammation. MBio (2015) 0.76
Comparison of virulence between the Yersinia pestis Microtus 201, an avirulent strain to humans, and the vaccine strain EV in rhesus macaques, Macaca mulatta. Hum Vaccin Immunother (2014) 0.75
Technical transformation of biodefense vaccines. Vaccine (2009) 0.75
Rational considerations about development of live attenuated Yersinia pestis vaccines. Curr Pharm Biotechnol (2013) 0.75
Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague. Vaccine (2016) 0.75
Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology. Adv Virus Res (2016) 0.75
A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis. Front Immunol (2017) 0.75
Yersinia pestis--etiologic agent of plague. Clin Microbiol Rev (1997) 14.63
A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature (1991) 13.19
Immunity to intracellular bacteria. Annu Rev Immunol (1993) 6.81
Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med (1997) 5.23
The role of multiplication of Pasteurella pestis in mononuclear phagocytes in the pathogenesis of flea-borne plague. J Immunol (1959) 5.13
CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A (2005) 3.30
Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun (1993) 3.16
Electron microscopic evidence for in vivo extracellular localization of Yersinia pseudotuberculosis harboring the pYV plasmid. Infect Immun (1990) 2.95
Plague bacillus: survival within host phagocytes. Science (1969) 2.85
Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine (1998) 2.75
Kinetics of disease progression and host response in a rat model of bubonic plague. Am J Pathol (2005) 2.56
Yersinia pestis grows within phagolysosomes in mouse peritoneal macrophages. Infect Immun (1984) 2.52
Effectiveness of live or killed plague vaccines in man. Bull World Health Organ (1970) 2.49
Immune responses to Yersinia enterocolitica in susceptible BALB/c and resistant C57BL/6 mice: an essential role for gamma interferon. Infect Immun (1994) 2.45
Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun (1995) 2.43
Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun (2003) 2.20
Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun (1996) 2.17
A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol (1995) 2.16
On natural and artificial vaccinations. Annu Rev Immunol (2001) 2.12
Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun (1996) 2.09
Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun (1997) 1.77
Expression of plasminogen activator pla of Yersinia pestis enhances bacterial attachment to the mammalian extracellular matrix. Infect Immun (1998) 1.76
Yersinia pestis (plague) vaccines. Expert Opin Biol Ther (2004) 1.72
T lymphocytes mediate protection against Yersinia enterocolitica in mice: characterization of murine T-cell clones specific for Y. enterocolitica. Infect Immun (1992) 1.66
Experimental Yersinia enterocolitica infection in euthymic and T-cell-deficient athymic nude C57BL/6 mice: comparison of time course, histomorphology, and immune response. Infect Immun (1993) 1.60
IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ T cells. J Immunol (1996) 1.50
Plague immunization. I. Past and present trends. J Infect Dis (1974) 1.42
Physiological basis of the low calcium response in Yersinia pestis. Infect Immun (1994) 1.31
The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol Med Microbiol (1999) 1.31
Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol (2004) 1.27
Pneumonic plague in an untreated plague-vaccinated individual. JAMA (1967) 1.24
Protective role for heat shock protein-reactive alpha beta T cells in murine yersiniosis. Infect Immun (1994) 1.13
Studies on immunization against plague. VIII. Study of three immunizing preparations in protecting primates against pneumonic plague. J Infect Dis (1955) 1.11
Yersinia pestis V protein epitopes recognized by CD4 T cells. Infect Immun (2005) 0.98
Protective Inoculation against Plague. J Med Res (1908) 0.82
Role of T-cell subsets in protection, delayed type of hypersensitivity and granuloma formation during Yersinia enterocolitica infection in mice. Immunol Lett (1996) 0.78
Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe (2009) 2.17
Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood (2002) 1.64
Neither fibrin nor plasminogen activator inhibitor-1 deficiency protects lung function in a mouse model of acute lung injury. Am J Physiol Lung Cell Mol Physiol (2008) 1.62
Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine (2011) 1.59
Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect Immun (2006) 1.47
Fibrin-mediated protection against infection-stimulated immunopathology. J Exp Med (2003) 1.43
Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect Immun (2006) 1.24
Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection. J Immunol (2009) 1.22
gamma-Herpesvirus-induced protection against bacterial infection is transient. Viral Immunol (2009) 1.19
Infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis. Infect Immun (2005) 1.15
IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection. J Immunol (2010) 1.10
Yersinia pestis evades TLR4-dependent induction of IL-12(p40)2 by dendritic cells and subsequent cell migration. J Immunol (2008) 1.08
Antibodies and cytokines independently protect against pneumonic plague. Vaccine (2008) 1.06
TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine (2010) 1.04
Thioredoxin reductase regulates the induction of haem oxygenase-1 expression in aortic endothelial cells. Biochem J (2006) 1.02
Yersinia pestis V protein epitopes recognized by CD4 T cells. Infect Immun (2005) 0.98
Exacerbated susceptibility to infection-stimulated immunopathology in CD1d-deficient mice. J Immunol (2005) 0.97
Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infections. J Immunol (2012) 0.97
Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague. J Immunol (2011) 0.96
D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague. Infect Immun (2009) 0.96
A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis. Infect Immun (2011) 0.96
Intact type 1 immunity and immune-associated coagulative responses in mice lacking IFN gamma-inducible fibrinogen-like protein 2. Proc Natl Acad Sci U S A (2004) 0.90
Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12Rbeta1 isoform that enhances DC migration. J Exp Med (2010) 0.89
Fibrinogen regulates the cytotoxicity of mycobacterial trehalose dimycolate but is not required for cell recruitment, cytokine response, or control of mycobacterial infection. Infect Immun (2009) 0.88
Enhanced 15-HPETE production during oxidant stress induces apoptosis of endothelial cells. Prostaglandins Other Lipid Mediat (2005) 0.88
Gamma interferon suppresses erythropoiesis via interleukin-15. Infect Immun (2007) 0.88
Selenium inhibits 15-hydroperoxyoctadecadienoic acid-induced intracellular adhesion molecule expression in aortic endothelial cells. Free Radic Biol Med (2007) 0.85
Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis. J Immunol (2013) 0.83
Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection. Infect Immun (2013) 0.82
Targeting mucosal immunity in the battle to develop a mastitis vaccine. J Mammary Gland Biol Neoplasia (2011) 0.82
Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis. Infect Immun (2011) 0.81
Tumor necrosis factor alpha and gamma interferon, but not hemorrhage or pathogen burden, dictate levels of protective fibrin deposition during infection. Infect Immun (2006) 0.81
Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice. J Autoimmun (2012) 0.75
Cutting edge technologies in animalomics. Vet Immunol Immunopathol (2010) 0.75
Bovine mammary dendritic cells: a heterogeneous population, distinct from macrophages and similar in phenotype to afferent lymph veiled cells. Comp Immunol Microbiol Infect Dis (2011) 0.75